Motif Bio announces US Army-funded evaluation of 'iclaprim'

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.
The AIM-traded firm said the aerosol technology allowed the delivery of antibiotics "painlessly and rapidly" into skin and soft tissue, with low-pressure and focused delivery.

It said the research was being funded through a grant from the US Department of Defense - Congressionally Directed Military Infectious Diseases Research Program, to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield.

"When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible," said Motif Bio chief medical officer David Huang.

"The data generated from [research lead] Dr Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."